2月5日,联邦制药全资附属公司珠海联邦生物医药有限公司研发的度普利尤单抗注射液(Dupilumab Injection)获得国家药品监督管理局出具的临床注册申请受理通知书,受理号:CXSL2600180,标志着联邦生物在自身免疫疾病治疗领域的创新研发取得阶段性成果。(图片来源:国家药品监督管理局官网)关于度普利尤单抗注射液药品名称:度普利尤单抗注射液适应症:特应性皮炎,本品用于治疗外用药控制不佳或...
Source Link2月5日,联邦制药全资附属公司珠海联邦生物医药有限公司研发的度普利尤单抗注射液(Dupilumab Injection)获得国家药品监督管理局出具的临床注册申请受理通知书,受理号:CXSL2600180,标志着联邦生物在自身免疫疾病治疗领域的创新研发取得阶段性成果。(图片来源:国家药品监督管理局官网)关于度普利尤单抗注射液药品名称:度普利尤单抗注射液适应症:特应性皮炎,本品用于治疗外用药控制不佳或...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.